Basit öğe kaydını göster

Effect of BG-12 on contrast-enhanced lesions in patients with relapsing-remitting multiple sclerosis: subgroup analyses from the phase 2b study

dc.contributor.authorMacManus, David G.
dc.contributor.authorLimmroth, Volker
dc.contributor.authorPolman, Chris H.
dc.contributor.authorSchmierer, Klaus
dc.contributor.authorYousry, Tarek A.
dc.contributor.authorMeluzinova, Eva
dc.contributor.authorDufek, Michal
dc.contributor.authorYang, Minhua
dc.contributor.authorDawson, Kate
dc.contributor.authorO'Neill, Gilmore N.
dc.contributor.authorEraksoy, Mefkure
dc.contributor.authorKappos, Ludwig
dc.contributor.authorGold, Ralf
dc.contributor.authorMiller, David H.
dc.contributor.authorHavrdova, Eva
dc.date.accessioned2021-03-04T14:48:59Z
dc.date.available2021-03-04T14:48:59Z
dc.date.issued2012
dc.identifier.citationKappos L., Gold R., Miller D. H. , MacManus D. G. , Havrdova E., Limmroth V., Polman C. H. , Schmierer K., Yousry T. A. , Eraksoy M., et al., "Effect of BG-12 on contrast-enhanced lesions in patients with relapsing-remitting multiple sclerosis: subgroup analyses from the phase 2b study", MULTIPLE SCLEROSIS JOURNAL, cilt.18, sa.3, ss.314-321, 2012
dc.identifier.issn1352-4585
dc.identifier.otherav_837d6510-8d02-4e5c-ab0d-e1c088c62db0
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/89506
dc.identifier.urihttps://doi.org/10.1177/1352458511421054
dc.description.abstractBackground: In a phase 2b study in patients with relapsing-remitting MS (RRMS), BG-12 240 mg three times daily significantly reduced the number of new gadolinium-enhanced (Gd+) lesions from weeks 12 to 24 (primary end point) by 69% compared with placebo.
dc.language.isoeng
dc.subjectYaşam Bilimleri
dc.subjectKLİNİK NEUROLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectNEUROSCIENCES
dc.subjectSinirbilim ve Davranış
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectNöroloji
dc.subjectTemel Bilimler
dc.titleEffect of BG-12 on contrast-enhanced lesions in patients with relapsing-remitting multiple sclerosis: subgroup analyses from the phase 2b study
dc.typeMakale
dc.relation.journalMULTIPLE SCLEROSIS JOURNAL
dc.contributor.departmentUniversitaet Basel (University Of Basel) , ,
dc.identifier.volume18
dc.identifier.issue3
dc.identifier.startpage314
dc.identifier.endpage321
dc.contributor.firstauthorID203765


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster